ADC Therapeutics Doses First Patient in a Phase I Clinical Trial of ADCT-502 in Patients with Advanced Solid Tumors with HER2 Expression
Trial to provide data on safety, tolerability, pharmacokinetics and efficacy
ADCT-502 represents ADC Therapeutic’s fourth ADC program in clinical trials
Lausanne, Switzerland, May 19, 2017 – ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that the first patient has been dosed in a Phase I clinical trial to evaluate its antibody drug conjugate (ADC) ADCT-502 in patients with advanced solid tumors with HER2 expression.
Press release in PDF: click here